EMA Application withdrawn: Graspa (asparaginase) — ERYTECH Pharma S.A.

View source ↗

Summary

EMA withdrawal of Graspa (asparaginase) application for Precursor Cell Lymphoblastic Leukemia-Lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Precursor Cell Lymphoblastic Leukemia-lymphoma

Drugs mentioned

• GRASPA (L-asparaginase encapsulated in red blood cells)

Snippet

Status: Application withdrawn. Therapeutic area: Precursor Cell Lymphoblastic Leukemia-Lymphoma. MAH: ERYTECH Pharma S.A.. Decision date: 29/06/2018. Orphan medicine